Abstract:Normal somatic cells have a finite number of divisions, a limited capacity to proliferate. Human telomeres, the long DNA TTAGGG repeats at the ends of chromosomes, are considered a molecular clock marker. The gradual and progressive telomere shortening at each replicative cycle is associated, through the activation of pRB and p53 pathways and genomic instability, to the replicative senescence, a non-dividing state and widespread cell death. Activation of telomere maintenance [telomerase; or alternative lengthening of telomeres mechanisms (ALT), or other adaptive responses] can revert this program. Although not completely known, several mechanisms and modulating agents may be able to up and down-regulate telomere length and its maintenance. Chemopreventive therapies for the up-regulation of telomerase activity, able to prolong the life of cell cultures in a phenotypically youthful state, could have important applications in research and medicine. On the contrary the therapeutic down-regulation of telomerase activity may be used in cancer therapy. Telomerase expression per se is not oncogenic, but telomere shortening and maintenance seem to be crucial events in tumor formation. Thus a particular focus has been pointed out relatively to the immortalization of normal or potential pre-cancerous cells. With the extension of life span the probability to get in contact with carcinogens increases, genetic instability, oncogene activation and/or onco-suppressor gene inactivation (i.e. p53, pRB, ras): the cancer transformation can be then induced in predisposed cells, depending on their genetic context, by the activation of telomere maintenance. Pharmacological intervention may be able to modulate the rate of living, by increasing life span of few specific target cells, or decreasing it in proliferating <cancer and pre-cancer cells>. Because of the unknown state of the enormous cell number of the human organism, is it safe to extend the human life span by therapeutic agents?

Telomere Dysfunction Induced by Chemotherapeutic Agents and Radiation in Normal Human Cells

Telomere length inversely correlates with radiosensitivity in human carcinoma cells with the same tissue background

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.

Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.

Effects of chemotherapeutic drugs on telomer of human liver cancer BEL-7404 cell

Research progress on anticancer therapeutics targeting telomere/telomerase

Relationship Between Telomere Length and Radiosensitivity in Various Human Cancer Cell Lines

Suppression of Telomere-Binding Protein TPP1 Resulted in Telomere Dysfunction and Enhanced Radiation Sensitivity in Telomerase-Negative Osteosarcoma Cell Line

Enhanced radiosensitivity by 6-thio-dG via increasing telomere dysfunction and ataxia telangiectasia mutated inhibition in non-small cell lung cancer

Radiation-induced senescence: therapeutic opportunities

Telomeres in toxicology: Occupational health

Telomere length maintenance in aging and carcinogenesis.

Telomere-Binding Protein TPP1 Modulates Telomere Homeostasis and Confers Radioresistance to Human Colorectal Cancer Cells

Slowly Repaired Bulky DNA Damages Modulate Cellular Redox Environment Leading to Premature Senescence

Increased Expression of Telomere-Related Proteins Correlates with Resistance to Radiation in Human Laryngeal Cancer Cell Lines

The Role of Telomeres and Telomerase in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation

Mouse Model: Telomeres and Telomerase in Stem Cell and Cancer

Telomere shortening and ageing

Ionizing Radiation-Induced Cellular Senescence in Normal, Non-transformed Cells and the Involved DNA Damage Response: A Mini Review

The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence

The long-term effects of chemotherapy on normal blood cells